Evidence map›Paper›PMID 39134001›Full record

ArticleMedical principles and practice : international journal of the Kuwait University, Health Science Centre2024

Acute Effect of Imeglimin Add-on Therapy on 24-h Glucose Profile and Glycemic Variability in Patients with Type 2 Diabetes Receiving Metformin.

Yasutake Shinohara, Teruo Jojima, Yusuke Kamiga, Shintaro Sakurai, Toshie Iijima, Takuya Tomaru, Ikuo Akutsu, Teruo Inoue, Isao Usui, Yoshimasa Aso

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical principles and practice : international journal of the Kuwait University, Health Science Centre, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yasutake ShinoharaDepartment of Endocrinology and Metabolism, Dokkyo Medical University, Mibu, Japan.
Teruo JojimaDepartment of Endocrinology and Metabolism, Dokkyo Medical University, Mibu, Japan.
Yusuke KamigaJapanese Red Cross Nasu Hospital, Otawara, Japan.
Shintaro SakuraiDepartment of Endocrinology and Metabolism, Dokkyo Medical University, Mibu, Japan.
Toshie IijimaDepartment of Endocrinology and Metabolism, Dokkyo Medical University, Mibu, Japan.
Takuya TomaruDepartment of Endocrinology and Metabolism, Dokkyo Medical University, Mibu, Japan.
Ikuo AkutsuJapanese Red Cross Nasu Hospital, Otawara, Japan.
Teruo InoueJapanese Red Cross Nasu Hospital, Otawara, Japan.
Isao UsuiDepartment of Endocrinology and Metabolism, Dokkyo Medical University, Mibu, Japan.
Yoshimasa AsoDepartment of Endocrinology and Metabolism, Dokkyo Medical University, Mibu, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionImeglimin is a novel antidiabetic drug with insulinotropic and insulin-sensitizing effects that targets mitochondrial bioenergetics. We investigated acute effects of add-on therapy with imeglimin to preceding metformin on the 24-h glucose profile and glycemic variability assessed by continuous glucose monitoring (CGM) in patients with type 2 diabetes.

methodsWe studied 30 outpatients with type 2 diabetes inadequately controlled with metformin. CGM was used for 14 days straight during the research period. Imeglimin 2,000 mg/day was started on day 7 after initiating CGM. Several CGM parameters were compared between days 4-6 (prior to imeglimin treatment) and 11-13 (following the initiation of imeglimin treatment).

resultsAfter treatment with imeglimin, 24-h mean glucose was acutely decreased from 161.6 ± 48.0 mg/dL to 138.9 ± 32.2 mg/dL (p < 0.0001), while time in range (i.e., at a glucose level of 70-180 mg/dL) was significantly increased from 69.9 ± 23.9% to 80.6 ± 21.0% (p < 0.0001). Addition of imeglimin to metformin significantly decreased the standard deviation (SD) of 24-h glucose and mean amplitude of glycemic excursions, 2 indexes of glycemic variability. Baseline serum high-density lipoprotein (HDL) cholesterol was negatively correlated with changes in mean 24-h glucose (r = -0.3859, p = 0.0352) and those in SD (r = -0.4015, p = 0.0309).

conclusionsImeglimin add-on therapy to metformin acutely lowered 24-h glucose levels and improved glycemic variability in patients with type 2 diabetes on metformin. A higher serum HDL cholesterol at baseline was associated with a better response to acute effects of imeglimin on 24-h glucose levels and glycemic variability.

Indexed as

Blood GlucoseDiabetes Mellitus, Type 2Hypoglycemic AgentsMetforminAdultAgedDrug Therapy, CombinationFemaleGlycated HemoglobinHumansMaleMiddle AgedTriazinesBlood GlucoseGlycated HemoglobinHypoglycemic AgentsimegliminMetforminTriazinesAcute effectContinuous glucose monitoringGlycemic variabilityImegliminMetforminTime in range

Identifiers

PMID39134001
PMCPMC11631041

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.